With ubituximab, a high percentage of patients maintained no signs of disease activity.

Published Date: 01 Mar 2023

After receiving ublituximab treatment, the majority of patients with relapsing multiple sclerosis showed that they could achieve and maintain no evidence of disease activity.

Read Full News

Latest News



Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Healthcare in the Mix in President Biden's Farewell Address

2.

Decoding calcifications in breast cancer: Towards personalized medicine

3.

Omicron Infections Are Usually Cleared Up in Immunocompromised Patients.

4.

For patients with clear cell renal cell carcinoma, a new PET agent allows for same-day imaging.

5.

Cabozantinib Improves PFS for Advanced Neuroendocrine Tumors


© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot